Bio-pharmaceutical company to explore collaboration opportunities during largest U.S. government-led trade and business development event
Rockville, MD – March 7, 2023 – Tasly Pharmaceuticals, Inc. (Tasly U.S.), “dedicated to a healthier world,” will participate in the Trade Winds ASEAN Mission and Business Forum March 13-15 in Bangkok, Thailand.
The Trade Winds event, organized by the U.S. Commercial Service (part of the U.S. Department of Commerce), is the largest U.S. government-led trade mission and business development forum. It will feature meetings with U.S. commercial diplomats and business representatives from more than 20 Asian countries, as well as opportunities for networking and dialogue.
Tasly U.S., whose vision is “to change the way the world takes and understands medicine,” will discuss its development of T89 (Dantonic), which has become the first herbal medicine-derived compound to complete a U.S. Food and Drug Administration Phase III global clinical trial, with promising data.
“Tasly U.S. is positioned to become a world-renowned innovator in pharmaceuticals, biologics, and nutraceuticals,” said Dr. He Sun, President and CEO of Tasly Pharmaceuticals, Inc. “We see the upcoming Trade Winds ASEAN Mission and Business Forum in Bangkok as an opportunity to introduce our capabilities, our products in development, and our unique perspective, to leading companies in the ASEAN region.”
In addition to presenting and discussing its products, used in the treatment of cardiovascular disease, non-alcoholic fatty liver disease (NAFLD), Tourette Syndrome, and others, Dr. Sun said Tasly U.S. looks forward to discussing business collaboration and drug co-development with other Trade Winds exhibitors and participants.
Trade Winds ASEAN Mission and Business Forum will take place at the Anatara and Avani Riverside Hotel in Bangkok March 13-15 from approximately 8:00 a.m. until 8:30 p.m. each day.
About Tasly U.S.
Tasly Pharmaceuticals, Inc. (Tasly U.S.) is “dedicated to a healthier world.” We provide effective, safe, and high-quality herbal-based alternative medicines for the benefit of the medical/healthcare community and its patients, and to provide solutions to reduce side effects caused by medications.
Founded in 2006, and following years of research and development, Tasly U.S., based in Rockville, Maryland, is positioned to become a world-renowned innovator in pharmaceuticals, biologics, and nutraceuticals.
Among its key accomplishments to date: T89 (Dantonic) has become the first herbal medicine-derived compound to complete an FDA Phase III global trial, yielding promising data. Results indicate that T89’s pharmacological functionalities express clinically significant benefits, including improving blood circulation, boosting energy metabolism level, and reducing blood viscosity.
Tasly U.S. believes its initial success with T89 will pave the way for the broader use of herbal medication as an effective and safe alternative to synthesized chemical and biological treatments.